Woodline Partners’s Silence Therapeutics SLN Stock Holding History
Bought
Maintained
Sold
Other funds holding SLN
SL
Woodline Partners's SLN Position: Q3 2026 in Review
Woodline Partners opened a new position in Silence Therapeutics (SLN) in Q3 2026: 300,000 shares worth $3.28M. The stake represents 0.01% of the portfolio and ranks #811 among its holdings. This is a return to the name: Woodline Partners previously reported a position in SLN as recently as Q3 2025.
Woodline Partners first reported a position in SLN in Q3 2022 and has held it in 14 quarters since. The position peaked at $7.4M in Q3 2024. 92 funds tracked by Wall St. Rank hold SLN as of Q3 2026.
- Woodline Partners held 300,000 shares of Silence Therapeutics worth $3.28M as of Q3 2026.
- Silence Therapeutics was a new Woodline Partners position in Q3 2026.
- Silence Therapeutics made up 0.01% of Woodline Partners's portfolio in Q3 2026, its #811 holding.
- Woodline Partners first reported a position in Silence Therapeutics in Q3 2022 and has held it in 14 quarters since.
- Woodline Partners's Silence Therapeutics position peaked at $7.4M in Q3 2024.
- 92 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2026.
Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.